Core Viewpoint - The Haikou National High-tech Industrial Development Zone aims to accelerate the development of its biopharmaceutical industry through open cooperation and platform construction, targeting a trillion-yuan biopharmaceutical industry cluster [1]. Group 1: External Cooperation - Haikou High-tech Zone is expanding its external cooperation scale, having signed the "Qiong-Hong Cooperation Memorandum" in March, establishing deep cooperation with Hong Kong Science Park in biopharmaceuticals, medical devices, and intelligent equipment [2]. - The establishment of the "Qiong-Hong Science and Technology Innovation Fund" aims to create a cross-border innovation network [2]. - The Haikou High-tech Zone is expected to achieve a biopharmaceutical industry output value exceeding 21.5 billion yuan in 2024 [2]. Group 2: Domestic Collaboration - The Haikou High-tech Zone has gathered over 90% of the province's pharmaceutical companies and is exploring cooperation with the Boao Lecheng International Medical Tourism Pilot Zone to form a "Lecheng Research + Haikou Production" model [3][4]. - This model facilitates the entire chain of overseas innovative drugs and medical devices for research and production in Hainan [4]. - The Haikou High-tech Zone is continuously promoting cooperation with Boao Lecheng to attract more international advanced medical devices [4]. Group 3: Inter-Provincial Linkage - The Haikou High-tech Zone has undertaken several cooperative projects with Guangdong, Hubei, and Shanghai, establishing cross-regional industrial, innovation, funding, and talent chains [5]. - The Guangdong-Hainan Advanced Manufacturing Cooperation Industrial Park has introduced 361 enterprises and 49 projects with a total investment of 11.9 billion yuan as of April this year [5][6]. - The Haikou Bio-City project, invested by Wuhan East Lake High-tech Group, represents a significant collaboration project in Hubei-Hainan cooperation [6].

Group 1 - The core viewpoint of the article highlights the efforts of the Boao Lecheng International Medical Tourism Pilot Zone in accelerating the development of a comprehensive pharmaceutical industry ecosystem through various initiatives, including the introduction of international innovative drugs and medical devices, local production, and the establishment of research and transformation platforms [1][2] Group 2 - The Lecheng Pilot Zone has introduced over 470 types of special drugs and medical devices through a green channel for real-world research, facilitating the registration and market entry of 21 products in China [1] - The "Lecheng + Haikou production" model has enabled the local production and approval of imported drugs, such as "Kisqali," which is set to commence production in Haikou National High-tech Zone in April 2024 [1] - The Pilot Zone has established partnerships with over 180 pharmaceutical and medical device companies from 20 countries, attracting major firms like Merck, Sonova, Gilead, Novartis, and others to set up R&D, trade, and production operations in Hainan [2] Group 3 - The Pilot Zone is enhancing its research capabilities by gathering high-quality medical resources and serving as a regulatory science research base for the National Medical Products Administration, with 30 medical institutions already operational [2] - An investment of nearly 1 billion yuan is being made to complete the Lecheng Medical Engineering Transformation Platform by the end of this year, which will be the first technology transfer and incubation platform in the innovative drug and medical device sector in Hainan [2] - The total scale of industry funds in the Lecheng Pilot Zone has reached 882 million yuan, supported by the successful introduction of three funds, including the Hainan Tourism Investment Health Industry Fund and the Lecheng Digital Therapy Fund [2]